{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:57:11Z","timestamp":1793717831296,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-980-6671"],"award-info":[{"award-number":["IN-US-980-6671"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-980-6671"],"award-info":[{"award-number":["IN-US-980-6671"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-980-6671"],"award-info":[{"award-number":["IN-US-980-6671"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-980-6671"],"award-info":[{"award-number":["IN-US-980-6671"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-980-6671"],"award-info":[{"award-number":["IN-US-980-6671"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-980-6671"],"award-info":[{"award-number":["IN-US-980-6671"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-980-6671"],"award-info":[{"award-number":["IN-US-980-6671"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-980-6671"],"award-info":[{"award-number":["IN-US-980-6671"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-980-6671"],"award-info":[{"award-number":["IN-US-980-6671"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-980-6671"],"award-info":[{"award-number":["IN-US-980-6671"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-024-01117-4","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T04:09:27Z","timestamp":1731643767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Identifying barriers to hepatitis B and delta screening, prevention, and linkage to care among people who use drugs in Philadelphia, Pennsylvania, USA"],"prefix":"10.1186","volume":"21","author":[{"given":"Beatrice","family":"Zovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Freeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Sapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anousha","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Jessop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Holbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Borondy-Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Plunkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chari","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"issue":"4","key":"1117_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5588\/pha.18.0093-ed","volume":"8","author":"D Richardson","year":"2018","unstructured":"Richardson D, Bell C. Public health interventions for reducing HIV, Hepatitis B and Hepatitis C infections in people who inject drugs. PHA. 2018;8(4):153. https:\/\/doi.org\/10.5588\/pha.18.0093-ed.","journal-title":"PHA"},{"key":"1117_CR2","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s10461-018-2293-0","volume":"23","author":"A Roth","year":"2019","unstructured":"Roth A, Tran N, Piecara B, Welles S, Shinefeld J, Brady K. Factors associated with awareness of pre-exposure prophylaxis for HIV among persons who inject drugs in Philadelphia: national HIV behavioral surveillance, 2015. AIDS Behav. 2019;23:1833\u201340. https:\/\/doi.org\/10.1007\/s10461-018-2293-0.","journal-title":"AIDS Behav"},{"issue":"9959","key":"1117_CR3","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(14)60220-8.","journal-title":"Lancet"},{"issue":"12","key":"1117_CR4","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/infdis\/jiy157","volume":"217","author":"P Mahale","year":"2018","unstructured":"Mahale P, Aka PV, Chen X, et al. Hepatitis D viremia among injection drug users in San Francisco. J Infect Dis. 2018;217(12):1902\u20136. https:\/\/doi.org\/10.1093\/infdis\/jiy157.","journal-title":"J Infect Dis"},{"key":"1117_CR5","doi-asserted-by":"publisher","unstructured":"Tressler S, Bhandari R. Interventions to increase completion of hepatitis B vaccination in people who inject drugs: a systematic review and meta-analysis. OFID. 2019;6(12). https:\/\/doi.org\/10.1093\/ofid\/ofz521.","DOI":"10.1093\/ofid\/ofz521"},{"issue":"3","key":"1117_CR6","doi-asserted-by":"publisher","first-page":"e35066","DOI":"10.2196\/35066","volume":"6","author":"ID Aronson","year":"2022","unstructured":"Aronson ID, Bennett AS, Ardouin-Guerrier MA, et al. How vaccine ambivalence can lead people who inject drugs to decline COVID-19 vaccination and ways this can be addressed: a qualitative study. JMIR Form Res. 2022;6(3):e35066. https:\/\/doi.org\/10.2196\/35066.","journal-title":"JMIR Form Res"},{"issue":"9","key":"1117_CR7","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","volume":"115","author":"JK Lim","year":"2020","unstructured":"Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of chronic hepatitis B virus infection in the United States. Am J Gastroenterol. 2020;115(9):1429\u201338. https:\/\/doi.org\/10.14309\/ajg.0000000000000651.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1117_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1177\/0033354920943528","volume":"135","author":"M Figgatt","year":"2020","unstructured":"Figgatt M, Hildick-Smith J, Addish E, et al. Susceptibility to hepatitis A and B virus among clients at a syringe services program in Philadelphia, 2018. Public Health Rep. 2020;135(5):691\u20139. https:\/\/doi.org\/10.1177\/0033354920943528.","journal-title":"Public Health Rep"},{"issue":"3","key":"1117_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","volume":"73","author":"AJ Stockdale","year":"2020","unstructured":"Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523\u201332. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.008.","journal-title":"J Hepatol"},{"key":"1117_CR10","unstructured":"Gish R. Diagnosing and screening for hepatitis D viral infection. [White paper]. Hepatitis B Foundation. 2022. https:\/\/www.hepb.org\/assets\/Uploads\/Gish-HDV-Diagnositic-Analysis-Whitepaper-1.pdf Hepatitis D Viral Infection. Accessed 14 Feb 2024."},{"issue":"1","key":"1117_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cgh.2019.05.047","volume":"18","author":"K Zhou","year":"2019","unstructured":"Zhou K, Terrault N. Gaps in viral Hepatitis awareness in the United States in a population-based study. Clin Gastroenterol Hepatol. 2019;18(1):188\u201395. https:\/\/doi.org\/10.1016\/j.cgh.2019.05.047.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"1117_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/jvh.13060","volume":"26","author":"H Kim","year":"2019","unstructured":"Kim H, Yang JD, El-Serag HB, Kanwal F. Awareness of chronic viral hepatitis in the United States: an update from the National Health and Nutrition Examination Survey. J Viral Hepat. 2019;26(5):596\u2013602. https:\/\/doi.org\/10.1111\/jvh.13060.","journal-title":"J Viral Hepat"},{"issue":"1","key":"1117_CR13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cgh.2019.05.047","volume":"18","author":"K Zhou","year":"2020","unstructured":"Zhou K, Terrault NA. Gaps in viral Hepatitis awareness in the United States in a population-based study. Clin Gastroenterol Hepat. 2020;18(1):188\u2013e1954. https:\/\/doi.org\/10.1016\/j.cgh.2019.05.047.","journal-title":"Clin Gastroenterol Hepat"},{"issue":"4","key":"1117_CR14","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399. https:\/\/doi.org\/10.1002\/hep.29800.","journal-title":"Hepatology"},{"issue":"9","key":"1117_CR15","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388. https:\/\/doi.org\/10.1177\/1049732305276687.","journal-title":"Qual Health Res"},{"issue":"11","key":"1117_CR16","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/jvh.12724","volume":"24","author":"A McLeod","year":"2017","unstructured":"McLeod A, Cullen BL, Hutchinson SJ, et al. Limited impact of awareness-raising campaigns on hepatitis C testing practices among general practitioners. J Viral Hepat. 2017;24(11):944\u201354. https:\/\/doi.org\/10.1111\/jvh.12724.","journal-title":"J Viral Hepat"},{"issue":"10","key":"1117_CR17","doi-asserted-by":"publisher","first-page":"100547","DOI":"10.1016\/j.jhepr.2022.100547","volume":"4","author":"A Palom","year":"2022","unstructured":"Palom A, Rando-Segura A, Vico J, et al. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Rep. 2022;4(10):100547. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100547.","journal-title":"JHEP Rep"},{"key":"1117_CR18","doi-asserted-by":"publisher","first-page":"108882","DOI":"10.1016\/j.drugalcdep.2021.108882","volume":"226","author":"O Price","year":"2021","unstructured":"Price O, Dietze P, Sullivan SG, Salom C, Peacock A. Uptake, barriers and correlates of influenza vaccination among people who inject drugs in Australia. Drug Alcohol Depend. 2021;226:108882. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108882.","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20133","key":"1117_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.drugalcdep.2011.10.009","volume":"123","author":"JN Park","year":"2012","unstructured":"Park JN, White B, Bates A, Enriquez J, Liao L, Maher L. Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs. Drug Alcohol Depend. 2012;123(1\u20133):35\u201340. https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.10.009.","journal-title":"Drug Alcohol Depend"},{"key":"1117_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12869","author":"M Harris","year":"2018","unstructured":"Harris M, Bonnington O, Harrison G, Hickman M, Irving W. Understanding hepatitis C intervention success: qualitative findings from the HepCATT study. Nottm Eprints. 2018. https:\/\/doi.org\/10.1111\/jvh.12869.","journal-title":"Nottm Eprints"},{"key":"1117_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.01.037.","journal-title":"Drug Alcohol Depend"},{"key":"1117_CR22","doi-asserted-by":"publisher","unstructured":"Austin EJ, Tsui JI, Barry MP, et al. Health care-seeking experiences for people who inject drugs with hepatitis C: qualitative explorations of stigma. J Subst Abuse Treat. 2022;137(108684). https:\/\/doi.org\/10.1016\/j.jsat.2021.108684.","DOI":"10.1016\/j.jsat.2021.108684"},{"issue":"5","key":"1117_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.disamonth.2018.12.002","volume":"65","author":"L Vearrier","year":"2019","unstructured":"Vearrier L. The value of harm reduction for injection drug use: a clinical and public health ethics analysis. Dis Mon. 2019;65(5):119\u201341. https:\/\/doi.org\/10.1016\/j.disamonth.2018.12.002.","journal-title":"Dis Mon"},{"issue":"4","key":"1117_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.nurpra.2021.12.028ve","volume":"18","author":"P Ghaswalla","year":"2022","unstructured":"Ghaswalla P, Davis K, Sweeney C, et al. Health care providers\u2019 knowledge, practices, and barriers to hepatitis vaccination guidelines. J Nurse Practitioners. 2022;18(4):403\u201310. https:\/\/doi.org\/10.1016\/j.nurpra.2021.12.028ve.","journal-title":"J Nurse Practitioners"},{"key":"1117_CR25","unstructured":"Department of Health and Human Services. Viral hepatitis national strategic plan: a roadmap to elimination for the United States (2021\u20132025). 2020. https:\/\/www.hhs.gov\/sites\/default\/files\/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf. Accessed 14 Feb 2024."},{"key":"1117_CR26","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jvh.13119","volume":"26","author":"AH Litwin","year":"2019","unstructured":"Litwin AH, Drolet M, Nwankwo C, et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE study. J Viral Hepat. 2019;26:1094\u2013104. https:\/\/doi.org\/10.1111\/jvh.13119.","journal-title":"J Viral Hepat"},{"issue":"13","key":"1117_CR27","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1080\/10410236.2020.1787927","volume":"36","author":"K Wilson","year":"2021","unstructured":"Wilson K, Bleasdale J, Przybyla SM. Provider-patient communication on pre-exposure prophylaxis (PrEP) for HIV prevention: an exploration of healthcare provider challenges. Health Commun. 2021;36(13):1677\u201386. https:\/\/doi.org\/10.1080\/10410236.2020.1787927.","journal-title":"Health Commun"},{"key":"1117_CR28","unstructured":"Centers for Disease Control and Prevention. Universal hepatitis B vaccination in adults aged 19\u201359 years: Updated recommendations of the Advisory Committee on Immunization Practices - United States. 2022. Centers for Disease Control and Prevention MMWR. 2022. https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7113a1.htm#:~:text=ACIP%20recommends%20that%20adults%20aged,B%20may%20receive%20HepB%20vaccines. Accessed 14 Feb 2024."},{"key":"1117_CR29","unstructured":"Centers for Disease Control and Prevention. Screening and testing for hepatitis B virus infection: CDC recommendations \u2013 United States. 2023. Centers for Disease Control and Prevention MMWR. 2023. https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/rr\/rr7201a1.htm. Accessed 14 Feb 2024."},{"key":"1117_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugpo.2017.07.022","volume":"47","author":"CW Helsper","year":"2017","unstructured":"Helsper CW, Janssen MP, van Essen GA, et al. Effectiveness and cost-effectiveness of a nationwide campaign for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands. Int J Drug Policy. 2017;47:117\u201325. https:\/\/doi.org\/10.1016\/j.drugpo.2017.07.022.","journal-title":"Int J Drug Policy"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01117-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01117-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01117-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T05:07:57Z","timestamp":1731647277000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01117-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1117"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01117-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of the City of Philadelphia Department of Public Health (Project Number: 2023-33) on August 7th, 2023, and Heartland IRB (Project Number: 02202023-457) on February 20th, 2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The Hepatitis B Foundation receives program and research grants from Gilead Sciences, VBI Vaccines, GSK, and Genentech. Beatrice Zovich has received compensation for serving on an advisory committee for Gilead Sciences, Inc. Chari Cohen sits on a patient advocacy advisory committee for GSK (with funds going to the Foundation).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}